There is evidence that obesity-related disorders are increased among people with depression. Variation in the FTO (fat mass and obesity associated) gene has been shown to contribute to common forms of human obesity. This study aimed to investigate the genetic influence of polymorphisms in FTO in relation to body mass index (BMI) in two independent samples of major depressive disorder (MDD) cases and controls. We analysed 88 polymorphisms in the FTO gene in a clinically ascertained sample of 2442 MDD cases and 809 controls (Radiant Study). In all, 8 of the top 10 single-nucleotide polymorphisms (SNPs) showing the strongest associations with BMI were followed-up in a population-based cohort (PsyCoLaus Study) consisting of 1292 depression cases and 1690 controls. Linear regression analyses of the FTO variants and BMI yielded 10 SNPs significantly associated with increased BMI in the depressive group but not the control group in the Radiant sample. The same pattern was found in the PsyCoLaus sample. We found a significant interaction between genotype and affected status in relation to BMI for seven SNPs in Radiant (P < 0.0057), with PsyCoLaus giving supportive evidence for five SNPs (P-values between 0.03 and 0.06), which increased in significance when the data were combined in a meta-analysis. This is the first study investigating FTO and BMI within the context of MDD, and the results indicate that having a history of depression moderates the effect of FTO on BMI. This finding suggests that FTO is involved in the mechanism underlying the association between mood disorders and obesity.
Introduction
In addition to unipolar major depressive disorder (MDD) being a major public health problem in its own right 1 there is growing evidence suggesting that rates of physical disease, such as obesity and diabetes, are elevated amongst people with depression. 2, 3 The study by Farmer et al. demonstrated a striking relationship between recurrent clinically sampled depression and increased body mass index (BMI), type 2 diabetes, coronary heart disease and hypertension. Regression analyses showed that the association of depression with this cluster of disorders (sometimes referred to as 'metabolic syndrome') was largely accounted for BMI. 2 A recent World Health Survey study involving 245 404 participants from 60 countries in regions all over the world found that the number of participants with one or more chronic physical disease, and comorbid depression, ranges from 9.3 to 23%. 3 Furthermore, recent studies support the hypothesis that there may be shared aetiological factors, including genetic factors, between recurrent unipolar depression, obesity and physical disorders. 2, 4 The fat mass and obesity-associated gene, FTO, on chromosome 16q has been reported multiple times to contribute to common forms of human obesity. 5 In 2007, two groups independently identified a common single-nucleotide polymorphism (SNP) in FTO (rs9939609) that was associated with BMI and an increased risk for adult obesity. 6, 7 In the same year, a third group performing a genome-wide association (GWA) study of BMI also found variants in FTO strongly associated with BMI and obesity-related traits. 8 Recently, the FTO association with BMI has also been replicated in two large GWA studies for obesity. 9, 10 These two studies strongly support the association between FTO variants and obesity.
Animal studies reported that FTO is widely expressed in the brain, with high expression in hypothalamic nuclei regulating energy balance. 11 Human studies have also found that the FTO variant (rs9939609) risk allele is associated with an increased energy intake 12, 13 and diminished satiety, 14 implicating FTO in the regulation of appetite.
This study explores the hypothesis that shared genetic aetiological factors exist between depression and obesity. Specifically, we aimed to investigate the influence of polymorphisms in FTO in relationship with BMI on a sample of depressed patients and psychiatrically healthy controls and follow-up the SNPs showing the strongest associations in an independent population-based cohort.
Materials and methods
Clinical sample Radiant Study. The depression case sample included 2442 individuals (740 men, 1702 women; mean age ± s.d.: 45.25 ± 12.15 years) and was sourced from several studies: the Depression Case-Control (DeCC) study, 15 Depression Network (DeNT) study 16, 17 and the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. 18 The DeCC sample comprises subjects with recurrent unipolar depression (minimum two episodes) of at least moderate severity as defined by DSM-IV or ICD-10 criteria, recruited from three UK sites (London, Cardiff and Birmingham). 15 Probands from the DeNT-affected sibling pair linkage study consisting of cases with recurrent unipolar depression of at least moderate severity collected at seven European sites and one US site. 16, 17 The GENDEP study includes individuals with an episode of depression of at least moderate severity recruited from nine European centres, 18 not necessarily recurrent. Either DSM-IV or ICD-10 diagnosis of depression were ascertained using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview in all three studies. 19 Individuals were excluded if they, or a first-degree relative, had a history of mania, hypomania, schizophrenia or bipolar disorder, or if the depression occurred in relation to alcohol, substance misuse or a medical illness or medication.
A total of 809 control individuals from the UK (313 men, 496 women; mean age±s.d.: 39.9±13.71 years) were screened for lifetime absence of any psychiatric disorder using a modified version of the Past History Schedule. 20 Participants were excluded if they, or a first-degree relative, ever fulfilled the criteria for depression, bipolar disorder or schizophrenia or if they scored 10 or above on the Beck Depression Inventory. 21 All cases and controls were of white European ancestry.
PsyCoLaus study. The sample is part of the PsyCoLaus study, which focused on psychiatric symptoms in a population-based cohort originally assessed for cardiovascular risk factors (CoLaus). CoLaus is a cross-sectional study including 6188 extensively phenotyped Caucasian individuals randomly selected from the list of residents of the city of Lausanne (Switzerland). All 35 to 66 year-old subjects of the CoLaus sample were invited to participate in the psychiatric evaluation for the PsyCoLaus sub-study (see Firmann et al. 22 and Preisig et al. 23 for a detailed description). The PsyCoLaus sample included 1296 cases (431 men, 862 women; mean age ± s.d.: 49.69 ± 8.68 years) who fulfilled lifetime ever criteria for MDD according to DSM-IV based on assessment using the Diagnostic Interview for Genetics Studies 24 . The 1690 PsyCoLaus subjects (974 men, 724 women; mean age ± s.d.: 50.59 ± 8.94 years) who have never fulfilled criteria for MDD were included as controls.
All studies were approved by the local ethical committees and informed written consent was obtained from all participants. Table 1 summarises the characteristics of the subjects in both studies.
Phenotypic data BMI was defined as weight (kilograms)/height (metres) 2 . In the Radiant study, self-reported height and weight were obtained during the SCAN interview for cases and during telephone interview for controls. In the PsyCoLaus sample, weight and height were measured with participants standing without shoes in light indoor clothes. 22 In both samples the distribution of BMI was positively skewed. We therefore transformed the data to log 10 (BMI) to achieve a closer approximation to normal distribution.
Genotyping
Radiant study. Depression cases and controls were genotyped using the Illumina HumanHap610-Quad BeadChips (Illumina Inc., San Diego, CA, USA) by the Centre National de Génotypage as previously Effect of the FTO gene on BMI M Rivera et al described. 25 After applying stringent quality control criteria for missing genotypes, departure from Hardy-Weinberg equilibrium and low minor allele frequency, a total of 88 SNPs spanning FTO ( ± 20 kbp either side, chr16: 52 295 376-52 705 882. UCSC March 2006) were included in the analyses.
PsyCoLaus study. Genotyping for depressive cases and controls was performed using the Affymetrix 500K SNP chip (Affymetrix Inc., Santa Clara, CA, USA). The genotyping are described in detail in the CoLaus 22 and PsyCoLaus 23 studies. Statistical analyses t-Test analyses were carried out to test the association between BMI and affected status in both studies.
In Radiant study linear regression models for quantitative traits assuming an additive genetic model were performed for each SNP to test for association between Log 10 BMI and FTO variants. The analyses were first carried out in the whole sample and then separately in the depressive cases and controls. Following the same procedures the most significant SNPs associated with Log 10 BMI in the Radiant sample were analysed in PsyCoLaus.
Affected status, gender and age were included as covariates in the regression analyses in both studies. Principal components were used to control for possible population stratification. In the Radiant study, we included centre of ascertainment as a covariate. We also tested for the interaction between FTO polymorphisms and affected status for an effect on Log 10 BMI.
The number of effective/independent tests in the Radiant data was calculated using the method of Galwey et al. 26 The significance was assessed by dividing 0.05 by the number of effective tests (calculated to be 44.8115), giving threshold of P < 0.0011.
The statistical analyses were performed using the statistical package PLINK v1.06 27 and the software Quicktest 28 in the Radiant and PsyCoLaus studies, respectively.
As the most strongly associated FTO polymorphism reported in literature so far is rs9939609, we used Beagle 29 to impute the genotypes for this SNP in the UK subsample of the Radiant study (1361 cases; 813 controls) using HapMap CEU samples as a reference panel. Two genotyped SNPs (rs8050136, rs3751812) are in absolute linkage disequilibrium (LD; r 2 = 1) with rs9939609, allowing imputation with high certainty. (For LD structure of the variants most significantly associated see Supplementary Figure 1. ) Analysis of imputed data was performed using gene dosage values. The regression analyses with the imputed variant were performed using R software.
Finally, we performed an interaction analysis between the most significant SNPs associated with Log 10 BMI and affected status in the combined Radiant and PsyCoLaus samples.
Results

BMI and depressive status
In Radiant, as previously reported in a subset of the same data, 2 there was a significant association between BMI and affected status. Depressed patients had significantly higher BMI values in comparison with controls in both men and women (men: t = À5.049, P = 0.007; women: t = À8.755, P < 0.0001). These results differ in the PsyCoLaus sample, in which there were no significant differences in BMI values between depressed cases and controls (men: t = À1.57, P = 0.117; women: t = À0.11, P = 0.913; Table 1 ).
FTO and Log 10 BMI All SNPs tested were in Hardy-Weinberg equilibrium (Radiant: P > 0.01; PsyCoLaus: P > 10 À4 ) in depressive cases and controls.
Radiant study. Following linear regression between the 88 FTO polymorphisms and Log 10 BMI, 9 of these SNPs located in the first intron of the gene were the most significantly associated with BMI using affected status, gender, age and principal components as covariates. Although these SNPs are mainly in high LD with each other (Figure 1 ), conditional analyses conducted on the most significant SNP (rs3751812) Effect of the FTO gene on BMI M Rivera et al suggested that they represent two independent signals. One signal includes SNPs rs7205986 and rs6499640, and the second signal includes the rest of the SNPs. Linear regression carried out with the imputed rs9939609 SNP in the UK subsample, also correcting for affected status, gender, age and principal components yielded a significant association with Log 10 BMI (b = À0.006, P = 0.0149). Linear regression in the depressive group with gender, age, principal components and study as covariates presented evidence of association for the same nine SNPs that were associated with Log 10 BMI in the combined sample. Moreover, the association between these SNPs and BMI was stronger when analysing the depressive group alone versus the combined sample. Seven remained statistically significant following multiple testing correction (see Table 2 ).
None of the SNPs tested for association between FTO and Log 10 BMI reached significant P-values in the control group alone. Results for the combined, case and control analyses are shown in Figure 1 .
Controlling for gender, age and principal components, rs9939609 was associated with Log 10 BMI in the depressive group (b = À0.011, P = 0.0007) but not in the control group (b = 0.003, P = 0.39). PsyCoLaus study. Out of the top 10 SNPs associated with BMI in the Radiant study, 8 had very high imputation accuracy (rSqHat > 0.9) and were included in association analyses. Linear regression analyses in combined depressive cases and controls yielded six SNPs significantly associated with Log 10 BMI when affected status, gender, age and principal components were used as covariates. Results carried out in the depressive group alone with gender, age and principal components covaried in the regression model yielded the same six SNPs significantly associated with Log 10 BMI ( Table 3) . As in the Radiant study, the analyses in the control group alone showed no significant associations with Log 10 BMI (Table 3) .
Interaction between FTO and affected status Radiant study. We found a significant interaction between genotype and affected status in relationship to Log 10 BMI, and found no significant interaction with gender (data not shown). An interaction between genotype and affected status was observed in seven SNPs (P < 0.0057; Table 2 ). We also found an interaction between the previously reported rs9939609 (the polymorphism most commonly associated with BMI in previous studies) and affected status in the UK Radiant subsample (b = À0.01, P = 0.0047) taking gender, age and principal components as covariates in the model.
Radiant and PsyCoLaus combined analysis.
Five of the seven SNPs with high imputation quality genotypes in PsyCoLaus, showed evidence (P-values between 0.03 and 0.06) of interaction between genotype and MDD-affected status in their effect on Log 10 BMI (Table 3 ). In addition, these SNPs were statistically significant in a meta-analysis of both cohorts ( Table 4 ). The Cochran Q P-values from the Effect of the FTO gene on BMI M Rivera et al test of heterogeneity of effects in each cohort were nonsignificant indicating that estimates were similar across the two cohorts and justifying the fixed effects meta-analysis (data not shown).
Discussion
We have investigated the influence of variants in FTO on BMI in a large clinical sample of depressed patients and controls (Radiant) to explore the genetic mechanism underlying the reported association between BMI or obesity and psychiatric disorders.
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We have then followed-up our findings in a population-based cohort (PsyCoLaus).We found associations between several SNPs in FTO and BMI that are in keeping with previous reports. However, an intriguing novel finding in the Radiant sample is that the association observed in the whole sample could be attributed to the depressive group, with none of the SNPs being significantly associated with BMI in the control sample alone, and the association strengthening when analysing the patients alone. A similar pattern was found in the PsyCoLaus sample, strongly arguing against this being a chance finding. There are two potential limitations of our study. The first is in the Radiant sample self-reported data were used to calculate BMI. Against this, height and weight were actually measured in the replication sample (PsyCoLaus) and the same pattern of results was found. The second limitation is that FTO polymorphism most frequently reported to be associated with BMI (rs9939609) in previous studies was here imputed rather than genotyped directly. Against this, the imputation was based on two genotyped SNPs (rs8050136, rs3751812) that are in absolute LD (r 2 = 1) with rs9939609. In the Radiant study, evidence that the observed FTO-BMI association is specific to the depressive sample is further supported by the interaction between FTO variants and affected status. This interaction was found in seven of the SNPs associated with BMI and indicates that the failure to observe an association in the control sample is unlikely to be a consequence of a lack of power. This suggests that the effect of the FTO gene on BMI is modified by having a depressive disorder. Furthermore, the interaction between FTO variants and affected status found in the Radiant data was corroborated by the combined results obtained from the Radiant and PsyCoLaus samples.
As this was the first study of its kind concerning the relationship between BMI and depression, we decided to interrogate the entire FTO gene. However, the evidence for the association with BMI was, as in previous studies not involved with depression, concentrated in a group of SNPs located in the first intron of the gene. Previous studies report association with SNPs located in the same region. [6] [7] [8] [9] [10] Interestingly, five associated SNPs (rs6499640, rs8050136, rs3751812, rs7190492 and rs8044769) in our sample have also been found to be genome-wide significantly associated with variation in BMI in the study by Thorleifsson et al. 9 Two of the most significant SNPs associated with BMI in Radiant and PsyCoLaus studies (rs3751812, rs8050136) are in absolute LD (r 2 = 1) with the FTO variant rs9939609. The results obtained with this imputed variant in both studies are in the same direction and confirm previous findings. [6] [7] [8] [33] [34] [35] [36] [37] In the Radiant study, depressed patients had higher BMI than controls and this could be attributable to a side effect of antidepressant treatment, or because people who are depressed carry out less physical activity and/or have an increased food intake. These effects are impossible to tease apart in the Radiant sample because all of the cases had at some point received antidepressants. Also, our control sample has been screened so as to have no history of psychiatric disorder in themselves or a first-degree relative. This is something previous studies investigating BMI, obesity and FTO have not done and could further explain why no association is observed in our control group.
In contrast, in the PsyCoLaus sample there were no statistically significant differences in BMI between depressed cases and controls. These differences possibly reflect the fact that Radiant is a clinically ascertained sample of mainly recurrent depression and all of the cases recruited have received antidepressant treatment, whereas the PsyCoLaus cases were recruited from the community and were an arguably less severe and more broadly defined group, in which only one episode was required for inclusion and in which only 37.5% of cases had ever received treatment with antidepressants. However, it is noteworthy that the regression of BMI on antidepressant status showed no hint of association (P = 0.573) nor was there any effect when antidepressant status was included as a covariate in the regression of BMI on FTO SNPs. These findings indicate that the moderating effect of depressive disorder on the BMI/FTO association is unlikely to be simply a result of taking antidepressants.
An alternative but not necessarily exclusive explanation is that depression and obesity involve pathophysiologically overlapping mechanisms. The Effect of the FTO gene on BMI M Rivera et al hypothalamic-pituitary-adrenocortical system governs the stress response and has been implicated in the aetiology of depression. 38 FTO is highly expressed in the hypothalamus, pituitary and adrenal glands indicating a possible role in the hypothalamicpituitary-adrenocortical axis, which is involved in body weight regulation. 39 Although several studies have investigated the influence of FTO variants on BMI, and the association between obesity and psychiatric disorders separately, to the authors' knowledge this is the first study investigating the relationship between FTO, BMI and psychiatric disorders (depression) concurrently. Our research suggests that although an association is observed in the whole sample, having a history of depression does in fact moderate the effect of FTO on BMI. The results found initially in the large clinical sample of depressed cases and controls (Radiant) have been replicated in a population-based cohort (PsyCoLaus). In addition, as milder forms of depression and depressive symptoms are very common in the general population 40 it is possible that experiencing such symptoms moderates the effect of FTO in the population as a whole and partly determines whom of those carrying ' at risk' FTO variants go on to become overweight or obese. 
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